Advances in Diagnosis and Therapy of Neuroendocrine Neoplasms
This Special Issue is dedicated to neuroendocrine neoplasms (NENs), a category of malignancy that demonstrates wide clinical heterogeneity, posing major challenges in diagnosis and management. There have been significant advances in the field of NEN genomics, pathology, imaging, and treatment over t...
Saved in:
Other Authors: | |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_68354 | ||
005 | 20210501 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20210501s2021 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-03943-746-7 | ||
020 | |a 9783039437450 | ||
020 | |a 9783039437467 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-03943-746-7 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a M |2 bicssc | |
100 | 1 | |a Segelov, Eva |4 edt | |
700 | 1 | |a Segelov, Eva |4 oth | |
245 | 1 | 0 | |a Advances in Diagnosis and Therapy of Neuroendocrine Neoplasms |
260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
300 | |a 1 electronic resource (144 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a This Special Issue is dedicated to neuroendocrine neoplasms (NENs), a category of malignancy that demonstrates wide clinical heterogeneity, posing major challenges in diagnosis and management. There have been significant advances in the field of NEN genomics, pathology, imaging, and treatment over the past five years. NENs are examples of rare tumours (although their incidence and prevalence are increasing) where international collaborative efforts have allowed the generation of high-level evidence to guide optimal patient-centred care. This issue presents both reviews and original papers to provide comprehensive state-of-the-art understanding of this fascinating disease. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Medicine |2 bicssc | |
653 | |a small bowel neuroendocrine tumours | ||
653 | |a pancreatic neuroendocrine tumours | ||
653 | |a liver metastases | ||
653 | |a midgut | ||
653 | |a meta-analysis | ||
653 | |a neuroendocrine tumors | ||
653 | |a carcinoid heart disease | ||
653 | |a carcinoid syndrome | ||
653 | |a somatostatin analogues | ||
653 | |a metastases | ||
653 | |a multidisciplinary | ||
653 | |a management | ||
653 | |a outcome | ||
653 | |a grading | ||
653 | |a staging | ||
653 | |a neuroendocrine neoplasms | ||
653 | |a chemotherapy | ||
653 | |a temozolomide | ||
653 | |a metronomic treatment | ||
653 | |a second-line | ||
653 | |a NOTCH | ||
653 | |a cancer-driven genes | ||
653 | |a mutational mechanism | ||
653 | |a germline mutations | ||
653 | |a small cell lung carcinoma | ||
653 | |a pancreatic NET | ||
653 | |a small bowel NET | ||
653 | |a medullary thyroid carcinoma | ||
653 | |a malignant castration-resistant prostatic cells | ||
653 | |a quality performance indicators | ||
653 | |a QPIs | ||
653 | |a cancer care | ||
653 | |a neuroendocrine tumour | ||
653 | |a NETs | ||
653 | |a modified Delphi | ||
653 | |a CommNETs | ||
653 | |a pancreatic neuroendocrine neoplasms | ||
653 | |a neuroendocrine tumor | ||
653 | |a long-term functional outcomes | ||
653 | |a pancreatectomy | ||
653 | |a diabetes mellitus | ||
653 | |a pancreatic exocrine insufficiency | ||
653 | |a body mass index | ||
653 | |a parenchyma-sparing surgery | ||
653 | |a neuroendocrine tumours | ||
653 | |a curative surgery | ||
653 | |a resection | ||
653 | |a follow-up | ||
653 | |a guidelines | ||
653 | |a relapse | ||
653 | |a recurrence | ||
653 | |a risk factor | ||
653 | |a mixed non-neuroendocrine neuroendocrine neoplasms | ||
653 | |a MiNENs | ||
653 | |a mixed adeno-neuroendocrine carcinoma | ||
653 | |a MANEC | ||
653 | |a 2017 WHO classification | ||
653 | |a 2019 WHO classification | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/3363 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/68354 |7 0 |z DOAB: description of the publication |